Drug intelligence / Profile preview

isotretinoin + interferon alfa-2b + docetaxel + estramustine

Development stage: Unknown
Lead developer: University of Medicine and Dentistry of New Jersey
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravenous, Oral, Subcutaneous, Intramuscular

Overview

R.I.T.E. is a combination chemo-immunotherapy regimen consisting of isotretinoin (13-cis retinoic acid), recombinant interferon alfa-2b, docetaxel (Taxotere), and estramustine phosphate sodium. Developed and studied by the University of Medicine and Dentistry of New Jersey (UMDNJ), this regimen was designed to treat hormone-refractory metastatic prostate cancer. The combination leverages multiple mechanisms: docetaxel stabilizes microtubules to inhibit cell division, estramustine disrupts microtubules and provides estrogenic effects, interferon alfa-2b acts as an immunomodulator and anti-proliferative agent, and isotretinoin promotes cell differentiation. By combining these diverse modalities, the R.I.T.E. regimen aims to overcome drug resistance and enhance tumor cell death in advanced prostate cancer patients.

Other names: RITE regimenRITE trial regimen13-cis retinoic acid + alpha interferon + docetaxel + estramustine

Targets

APC (Activated protein C)IFNAR (Immune system modulation via type I interferon receptor)RAR (Retinoic acid receptor)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on isotretinoin + interferon alfa-2b + docetaxel + estramustine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on isotretinoin + interferon alfa-2b + docetaxel + estramustine.

Explore the full profile